Europe Therapeutic Drug Monitoring Market

Europe Therapeutic Drug Monitoring Market Size (2023 to 2028)

The size of the therapeutic drug monitoring market in the European region is expected to grow at a CAGR of 6.51% from 2023 to 2028 and be worth USD 0.75 billion by 2028 from USD 0.55 billion in 2023.

The growing demand for personalized medicine across the European region is propelling the growth of the European therapeutic drug monitoring market. Owing to the awareness of the benefits of personalized medicine, much of the European population has adopted personalized medicine in recent years. Personalized medicine offers faster recovery from diseases than traditional medicine and is manufactured by taking patient data and some patient samples. During the development of personalized medicine, they also conduct a therapeutic drug monitoring process by taking the patient's samples, such as saliva, to enquire about the concentration of the drugs that need to be administered to recover with no side effects.

The growing number of organ transplant procedures and increasing demand for therapeutic monitoring devices are fuelling the growth rate of the European market. Immunosuppressive therapy plays a significant role in the transplantation procedure. Immunosuppressive therapy helps reduce the organ's rejection from the receptor body. After the transplantation procedures, managing immunosuppressive therapies requires therapeutic drug monitoring, which helps decide the drug concentration. Increasing research on developing therapeutic drug monitoring for various types of diseases also helps the market grow. Digital technologies with therapeutic drug monitoring are favoring regional market growth in the coming years.

The growing number of investments by governmental organizations and pharmaceutical companies are favoring the growth of the European therapeutic drug monitoring market. In addition, there has been a rise in the number of clinics for trials to increase the success rate in therapeutic drug monitoring, which helps in testing certain drug quality for the individual.

On the other hand, the high cost of drug monitoring tests is hampering the growth of the European therapeutic drug monitoring market. In addition, an alternative procedure to therapeutic drug monitoring and a lack of skilled professionals in developing advanced drug monitoring is the other factors hampering the market growth during the forecast period in the European region.

This research report on the European therapeutic drug monitoring market has been segmented and sub-segmented into the following categories.

By Product:

• Consumable
• Equipment

The consumable segment had the major share of the European therapeutic drug monitoring market in 2021.

By Technology:

• Fluorescence Immunoassay
• Radioimmunoassay
• GCMS

The fluorescence immunoassays segment is expected to play the leading role in the European market during the forecast period.

By Drug Class:

• Antiepileptics
• Antibiotics
• Psychoactive Drugs
• Antiarrhythmic Drugs
• Bronchodilators
• Immunosuppressants
• Others

The antiepileptic segment is predicted to hold a major share of the European therapeutic drug monitoring market during the forecast period.

By End-User:

• Hospitals
• Commercial/Private Laboratories
• Others

The hospital segment is anticipated to hold the most significant share of the European market during the forecast period.

By Country:

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

Geographically, the European region is predicted to control a substantial share of the worldwide market during the forecast period owing to the growing number of advancements in the healthcare sector and increasing health consciousness among the European population. Epilepsy is a severe neurological disorder that results in unprovoked seizures, neurobehavioral psychosocial consequences, and premature mortality. According to recent reports, nearly 6 million people have epilepsy. Epilepsy disease is mainly seen in older adults. Therapeutic drug monitoring plays a significant role in deciding the number of drugs taken by the individual to reduce the side effects of the drug overdose and results in helping to cure the patient over time.

The UK led the therapeutic drug monitoring market in Europe in 2021 and is expected to witness a notable CAGR during the forecast period owing to the growing number of therapeutic drug monitoring programs in childhood centers across the UK. Chemotherapeutic in children plays a challenging role resulting in several physiological changes in the first few months of the treatment. To reduce the severe side effect in children who are taking chemotherapy for cancer treatment, these children's patients prefer to take drug therapeutic monitoring tests to test the level of the drugs that the children can take for the therapy.

The German therapeutic drug monitoring market is estimated to hold a considerable share of the European market during the forecast period. The increasing awareness of therapeutic drug monitoring by healthcare organizations and major market players drives the growth of the German market. These awareness programs provide complete information to the population suffering from various types of disease and having side effects due to using low or high doses of medications.

KEY MARKET PLAYERS:

Companies playing a prominent role in the European therapeutic drug monitoring market profiled in this report are Abbott Laboratories, Inc., Agilent Technologies, Inc., Alere, Inc., apDia Group, ARK Diagnostics, Inc., Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche AG, and Grifols, S.A.